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BACKROUND: Experimental evidence indicates that certain drugs, that are secondary or tertiary amines or
amides, form N-nitroso compounds in the presence of nitrite in an acidic environment. Nitrosatable drugs
have been associated with birth defects in a few epidemiologic studies. This study describes the prevalence
and patterns of nitrosatable drug use among U.S. women during early pregnancy and examines maternal
factors associated with such use. METHODS: Data were analyzed from the National Birth Defects Prevention
Study and included 6807 mothers who gave birth to babies without major congenital malformations during
1997 to 2005. Information was collected by telephone interview about medication use, demographic factors,
and maternal health. Drugs taken during the ﬁrst trimester were classiﬁed according to nitrosatability, amine
and amide functional groups, and primary indication of use. RESULTS: Approximately 24% of the women
took one or more nitrosatable drugs during the ﬁrst trimester, including 12.4%, 12.2%, and 7.6% who respec-
tively took secondary amines, tertiary amines, or amides. Five of the ten most commonly taken drugs were
available over the counter. Women who were non-Hispanic white (29.5%), with 1 year or more college edu-
cation (27.3%) or 40 years or older (28.8%) had the highest prevalence of use. Supplemental vitamin C, an in-
hibitor of nitrosation, was not taken by 41.6% and 19.3% of nitrosatable drug users during the ﬁrst and sec-
ond months of pregnancy, respectively. CONCLUSIONS: In this U.S. population, ingestion of drugs classiﬁed
as nitrosatable was common during the ﬁrst trimester of pregnancy, especially among non-Hispanic white,
more educated, and older mothers. Birth Defects Research (Part A) 91:258–264, 2011.  2011 Wiley-Liss, Inc.
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amine
INTRODUCTION
Extensive experimental evidence indicates that N-ni-
troso compounds can be formed in vivo via the reaction
of nitrosatable amines or amides and nitrosating agents
such as nitrite in an acidic environment, as is found in
the stomach (Preussmann, 1984). A variety of drugs have
been classiﬁed as contributing amines (secondary or terti-
ary) or amides in the endogenous formation of N-nitroso
compounds (Lijinsky, 1974). Supporting evidence for
these classiﬁcations comes from standardized experi-
ments of speciﬁc compounds using the World Health Or-
ganization Nitrosation Assay Procedure (Gillatt et al.,
1984; Brambilla et al., 1985) or simulated human gastric
conditions (Ziebarth and Teichmann,1980; Gillatt et al.,
1984; Sakai et al., 1984; Gillatt et al., 1985; Ohta et al.,
1986; Ziebarth et al., 1989) that resulted in the production
and identiﬁcation of nitrosamines and nitrosamides. In
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groups had greater yields of N-nitroso compounds than
did those containing tertiary amines; however, nitro-
sation of tertiary amines and amides resulted in the
production of known carcinogens (e.g., n-nitrosodime-
thylamine, nitrosoureas). In addition, drugs have been
classiﬁed as theoretically nitrosatable through evaluation
of their chemical structure (McKean-Cowdin et al., 2003),
or through genotoxic testing of nitrosation products, with
and without identiﬁcation of speciﬁc N-nitroso com-
pound (Andrews et al., 1980; Alba et al., 1988; Ozhan
and Alpertunga, 2003).
In a series of experiments on mice, Platzek et al. (1983)
noted that acetoxymethyl-methylnitrosamine, which has
the same active intermediate metabolite as n-nitrosodime-
thylamine, increased exencephaly, cleft palate, limb mal-
formations, and other skeletal anomalies at doses not
associated with maternal toxicity. It is noteworthy that a
sizable number of nitrosatable drugs form n-nitrosodime-
thylamine in the presence of nitrite (McKean-Cowdin
et al., 2003; Brambilla and Martelli, 2007).
To date, ﬁve epidemiologic studies have examined the
relation between maternal exposure to nitrosatable drugs
and birth defects in offspring. Using data from the Col-
laborative Perinatal Project, Olshan and Faustman (1989)
identiﬁed a total of 13 nitrosatable drugs taken during
the ﬁrst 4 months of pregnancy. Relative to women not
taking these drugs, women who took one or more nitro-
satable drugs were more likely to have infants with eye,
musculoskeletal, or gastrointestinal malformations;
hydrocephaly; craniosynostosis; or spina biﬁda. Findings
of two subsequent studies (Gardner et al., 1998; Kallen
and Robert-Gnansia, 2005) indicated positive associations
between prenatal exposure to three of the drugs identi-
ﬁed by Olshan and Faustman (1989) as nitrosatable
(chlordiazepoxide, nitrofurantoin, and chlorpheniramine)
and craniosynostosis. In a study of nitrates and neural
tube defects, Croen et al. (2001) also used the Olshan and
Faustman list to classify women’s exposure to nitrosat-
able drugs and found no association between taking such
drugs and neural tube defects. However, Brender et al.
(2004) noted a signiﬁcant positive association between
reported use of drugs with potential for nitrosation and
neural tube defects in offspring among Mexican Ameri-
can women who also had a higher dietary intake of
nitrites.
Results of two epidemiologic studies have also sug-
gested an association between prenatal exposure to nitro-
satable drugs and childhood cancer (Preston-Martin
et al., 1982; Olshan and Faustman, 1989), although four
subsequent studies found no association between these
drug exposures and childhood brain tumors (Carozza
et al., 1995; McKean-Cowdin et al., 2003; Cardy et al.,
2006) or neuroblastoma (Cook et al., 2004).
Exposure measurement was a limitation in previous
epidemiologic studies of prenatal exposures of nitrosat-
able drugs. First, study participants were often asked to
recall drug use in pregnancies that occurred up to 20
years earlier in the childhood cancer studies (Preston-
Martin et al., 1982; Carozza et al., 1995; McKean-Cowdin
et al., 2003; Cook et al., 2004; Cardy et al., 2006). Second,
classiﬁcations of drugs as nitrosatable were incomplete
(Preston-Martin et al., 1982; Olshan and Faustman, 1989;
Carozza et al., 1995; Gardner et al., 1998; Brender et al.,
2004). Brambilla and Martelli (2007) identiﬁed 182 drugs
that had been tested, of which 173 (95%) were found to
form N-nitroso compounds or other reactive species, and
they acknowledged the possibility that additional pub-
lished and unpublished results could extend this list.
Only one of the previous birth defect studies classiﬁed
nitrosatable drugs by indication of use, and none classi-
ﬁed these drugs by molecular structure (i.e. secondary
amines, tertiary amines, or amides). Research has also
indicated that certain compounds can inhibit endogenous
nitrosation, with ascorbic acid being the most thoroughly
studied (Mirvish, 1994). Brambilla and Martelli (2007)
noted that the formation of N-nitroso compounds from
drug-nitrite interactions could be reduced by taking
ascorbic acid with nitrosatable drugs. Previous studies
have not reported prevalence of vitamin C supplementa-
tion among women who took drugs classiﬁed as nitrosat-
able or indicated the effects of vitamin C intake on any
associations between nitrosatable drug use and adverse
pregnancy outcomes. Accounting for vitamin C use when
assessing the effects of nitrosatable drugs on pregnancy
outcomes may prove to be critically important. The pur-
pose of our study was (1) to describe the prevalence and
patterns of nitrosatable drug use among U.S. women
during the ﬁrst trimester of pregnancy, including type of
drug (secondary or tertiary amine, amide) and indication
of use; (2) to examine maternal factors associated with
nitrosatable drug use; and (3) to investigate the preva-
lence of supplemental vitamin C use among women who
took nitrosatable drugs in early pregnancy.
MATERIALS AND METHODS
Study Population
To assess the prevalence, patterns of use, and factors
related to nitrosatable drug use among childbearing
women, we used data from the National Birth Defects
Prevention Study (NBDPS), an ongoing population-based
case-control study of birth defects in the United States
that began in 1997. Ten Centers for Birth Defects
Research and Prevention (CBDRP; Arkansas, California,
Georgia, Iowa, Massachusetts, New Jersey [1998 to 2002],
New York, North Carolina [2003 to present], Texas, and
Utah [2003 to present]) participate in this national study.
Mothers of cases and controls were invited to participate
within 24 months after the expected due date of the
index pregnancy. Information about the study popula-
tions and methods used in the NBDPS has been
described in detail elsewhere (Yoon et al., 2001). The
institutional review boards in each state and the Centers
for Disease Control and Prevention approved the study
protocol, and the Texas A&M Institutional Review Board
also approved the project from which the present analy-
sis is a substudy.
Analyses for our study included control women only,
whose pregnancy due dates were between October 1,
1997, and December 31, 2005. Control-infants were live
births without major birth defects who were residents of
the geographic areas covered by one of the CBDRP popu-
lation registries at the time of delivery. These controls
were selected randomly from either live birth certiﬁcates
(Iowa, Massachusetts, New Jersey, Metropolitan Atlanta,
North Carolina, and Utah) or hospital records (New
York, California, Arkansas, and Texas) (Centers for Dis-
ease Control and Prevention, 2005). For those states that
selected controls from hospitals, a systematic random
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portion to the number of births in each hospital in a
given geographic area (Yoon et al., 2001). Control-infants
were not eligible if they had a major birth defect, were
not a resident of one of the geographic areas covered by
CBDRP, were adopted or in foster care, had a deceased
mother, or were stillborn (The National Birth Defects Pre-
vention Study Prototcol, Centers for Disease Control and
Prevention, 2005).
Data Collection
As part of the NBDPS, women were interviewed by
telephone by trained interviewers with a standard ques-
tionnaire after oral informed consent was obtained. The
interview lasted for approximately 1 hour and covered
topics regarding maternal health (diseases and illnesses,
fever, injuries, medications), pregnancy issues (pregnancy
history, prenatal care, morning sickness); diet or sub-
stance abuse (vitamins, food supplements, dietary assess-
ment, caffeine consumption, tobacco, alcohol, street
drugs), demographic characteristics, and occupational
and environmental exposures (Yoon et al., 2001). Women
were questioned about drugs taken (start and stop dates,
frequency of use) for speciﬁc illnesses and diseases (e.g.,
asthma, diabetes, high blood pressure, infections, respira-
tory illnesses, seizures) and about speciﬁc products (e.g.,
ampicillin, metoprolol, propranolol, phenytoin, pseudoe-
phedrine). From these interviews, reported products
were linked to their active ingredients by the Slone Epi-
demiology Center Drug Dictionary (Kelley et al., 2003).
Women were also questioned about vitamin use, includ-
ing prenatal vitamins, multivitamins, and single vitamins.
A total of 6807 (66.2%) of eligible control mothers
(expected delivery dates between October 1, 1997, and
December 31, 2005) participated in the interview.
Classiﬁcation of Nitrosatable Drugs
All orally administered prescription and nonprescription
medications reported by control women and their active
ingredients were ﬁrst identiﬁed. Orally inhaled medications
(e.g., albuterol, epinephrine) were included because they
may be deposited in the mouth and throat, mixed with sa-
liva, and swallowed. Products applied topically to the mu-
cous membranes of the eye and nose were excluded. The
resulting group of active ingredients was cross-referenced
against previously compiled lists of nitrosatable medicinal
compounds (McKean-Cowdin et al., 2003; Brambilla and
Martelli, 2007) and categorized based on the presence of
amine (primary, secondary, tertiary) and amide functional
groups in their chemical structure. Primary amines do not
form stable N-nitroso compounds and were excluded. A
number of compounds were available for inclusion in mul-
tiple categories (e.g., atenolol is both a secondary amine
and amide). The structures of all remaining active ingre-
dients were evaluated for the presence of amine and amide
functional groups and were checked for any additional
published evidence of nitrosatabilty using Medline and
Internet sources. Finally, each component was categorized
by its primary indication or therapeutic use (e.g., analgesic,
antiinfective) and pharmacologic class (e.g., opioid, macro-
lide; Supplemental Table 1).
A dataset for each nitrosatable component was created
with the NBDPS Data Analysis Tools and Database Ver-
sion 7.04, Medication Exposure Data Set Creation System,
that included variables for whether the drug was taken
during the ﬁrst trimester and the number of days taken
during that period. Individual drug components were
grouped into their respective nitrosatable groups (sec-
ondary amines, tertiary amines, amides) and indication
groups (e.g., analgesic, antihistamine, stimulant).
Data Analysis
Prevalence of intake by nitrosatable category, therapeu-
tic use, and individual components was calculated by
dividing the number of NBDPS participants who reported
taking the respective components during the ﬁrst trimester
of pregnancy by the total number of women for which
use of that component or groups of components was
known (excluding unknowns). We also calculated preva-
lence of nitrosatable use by various maternal characteris-
tics, including maternal race or ethnicity (non-Hispanic
white, non-Hispanic black, Hispanic, Asian, Paciﬁc Is-
lander, other); age at delivery (seven age groups), and
years of education (0 to 8 years, 9 to 11 years, 12 years, 13
to 15 years, >15 years). Prevalence of use by state of resi-
dence was adjusted by maternal race or ethnicity using
direct adjustment procedures (Szklo and Nieto, 2007) and
the racial or ethnic distribution of all NBDPS comparison
mothers combined as the standard population. Secular
trends of nitrosatable drug use were examined for
expected dates of delivery from 1997 to 2005. Although
we focused on nitrosatable drug use during the ﬁrst tri-
mester, we also examined the prevalence of these drug
exposures during the periconceptional period (1 month
before to 1 month after conception), the exposure window
that would be more relevant for some malformations such
as neural tube defects. Because vitamin C supplement use
varied considerably by month during the ﬁrst trimester,
we examined prevalence of supplement use (none, less
than daily, daily) separately during the ﬁrst, second, and
third months of pregnancy by nitrosatable drug use dur-
ing the ﬁrst trimester.
RESULTS
A total of 1572 (23.6%) of women took one or more
nitrosatable drugs during the ﬁrst trimester of pregnancy.
Approximately 12% of women reported taking drugs that
were secondary or tertiary amines, with 7.6% reporting
use of drugs classiﬁed as nitrosatable amides. The most
common indications of use varied by drug category, with
decongestants, asthma medications, and antidepressants
being the most common among secondary amines. Anti-
histamines, antiemetics, and cough suppressants were
the most common tertiary amines, and antiinfectives and
stimulants (e.g., caffeine) were the most common amide
drugs (Table 1). Although rank varied by category, the
most common nitrosatable components included pseu-
doephedrine (7.7% of the women), amoxicillin (4.0%),
promethazine (3.1%), albuterol (2.7%), dextromethorphan
(2.1%), diphenhydramine (1.7%), chlorpheniramine
(1.6%), doxylamine (1.2%), caffeine (1.0%), and ﬂuoxetine
(0.8%; Table 2).
During the ﬁrst trimester, the prevalence of nitrosat-
able drug use varied by maternal race or ethnicity, age,
and education in this study population (Fig. 1). Non-His-
panic white women had the highest prevalence of nitro-
satable drug use during this period (29.5%) as well as for
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amines (15.2%), and amides (9.5%). Hispanic women
reported the lowest use (11.6%) of nitrosatable drugs. Prev-
alence of use of these drugs generally increased with
maternal age, although less of an age trend was noted with
nitrosatable amide drugs. Women who had 1 year or more
of college were more than twofold as likely (27.3%) than
w o m e nw i t hl e s st h a n9y e a r so fe d u c a t i o n( 1 0 . 7 % )t ou s e
any nitrosatable drugs. This educational pattern was stron-
ger for secondary and tertiary amines than for amides.
Adjustment for maternal race or ethnicity reduced prev-
alence differences of nitrosatable drug use by state of resi-
dence, although some variation still remained by geo-
graphical area (Fig. 2). NBDPS control mothers who
resided in Arkansas had the highest prevalence of nitro-
satable drug use overall (28.0%), for tertiary amines
(17.8%) and amides (8.5%), but California participants had
the highest prevalence of secondary amine use (15.3%).
For the period of 1997 to 2005, prevalence of any nitro-
satable drug use varied only minimally by year, ranging
from 22.4% in 2001 to 24.5% in 2004 (data not shown).
No overall secular trends were noted for secondary and
tertiary amines or amides.
During the periconceptional period, 16.8% of women
reported taking one or more nitrosatable drugs, and
approximately 10%, 9%, and 5% reported taking drugs
classiﬁed as secondary amines, tertiary amines, or
amides, respectively. Similar to patterns noted for the
ﬁrst trimester, women who took nitrosatable drugs dur-
ing the periconceptional period were most likely to be
non-Hispanic white (21.5%), have 1 year or more of col-
lege education (19.4%), or be 40 years or older (22.1%).
Among women who took nitrosatable drugs, <40%
reported daily use of a supplement with vitamin C dur-
ing the ﬁrst month of pregnancy (Table 3), although
Table 2
Most Commonly Used Nitrosatable Drug Components
during the First Trimester of Pregnancy, National Birth
Defects Prevention Study Control Women, 1997–2005
Nitrosatable Drug Components
a Number %
Any secondary amine (24 components)
b 828 12.4
Albuterol 178 2.7
Fluoxetine 53 0.8
Paroxetine 36 0.5
Pseudoephedrine 515 7.7
Ranitidine 29 0.4
Any tertiary amine (51 components)
b 820 12.2
Chlorpheniramine 104 1.6
Dextromethorphan 139 2.1
Diphenhydramine 115 1.7
Doxylamine 82 1.2
Promethiazine 207 3.1
Any amide (22 components)
b 512 7.6
Amoxicillin 271 4.0
Caffeine 64 1.0
Cephalexin 44 0.7
Metoclopramide 25 0.4
Sulfamethoxazole 38 0.6
aComplete information available for 6649 women for any
nitrosatable drugs, 6678 women for any secondary amines, 6708
women for any tertiary amines, and 6701 women for any
amides.
bThe ﬁve most common components listed under each class of
nitrosatable drugs.
Table 1
Prevalence of Nitrosatable Drug Use by Indication
during the First Trimester of Pregnancy, National Birth
Defects Prevention Study Control Women, 1997–2005
Nitrosatable Drug Components
a Number %
Any nitrosatable drug 1572 23.6
Any secondary amine
b 828 12.4
Asthma medications: beta adrenergic 182 2.7
Antidepressant medications 92 1.4
Selective serotonin reuptake inhibitor 88 1.3
Tricyclic 4 0.1
Cardiovascular medications 32 0.5
Beta blocker 23 0.3
Thiazide diuretic 6 0.1
Decongestant 518 7.8
Antidiabetic, biguanide
c 16 0.2
Gastrointestinal, H2 blocker 30 0.4
Muscle relaxant, migraine 7 0.1
Any tertiary amine
b 820 12.2
Analgesic 91 1.4
Opoids 86 1.3
Anticholinergic 14 0.2
Antidepressant, Tricyclic 5 0.1
Antidiabetic, Biguanide
c 16 0.2
Antidiarrheal, Opoid 1 0.0
Antiemetic-prokinetic 253 3.8
Antihistamine 12 0.2
Phenothiazine 224 3.3
Prokinetic
d 25 0.4
Antiepileptic
e 10 0.1
Antihistamine 336 5.0
Antiinfective 38 0.6
Macrolide 27 0.4
Tetracylines 3 0.0
Benzodiazepine 8 0.1
Cardiovascular 9 0.1
Beta blocker 1 0.0
Calcium channel blocker 3 0.0
Antihypertensives
f 5 0.1
Cough suppressant 139 2.1
Gastrointestinal, H2 blocker 30 0.4
Migraine 6 0.1
Nicotine replacement 1 0.0
Stimulant
g 64 1.0
Any amide
b 512 7.6
Antiemetic-prokinetic
d 37 0.6
Antiepileptic 16 0.2
Antiinfective 375 5.6
B-Lactam 334 5.0
Macrolide 3 0.0
Sulfonamide
h 38 0.6
Tetracyclines 3 0.0
Benzodiazepine 10 0.1
Cardiovascular 17 0.3
Beta-blocker 11 0.2
Calcium channel blocker 1 0.0
Diuretic 6 0.1
Migraine 6 0.1
Stimulant
g 64 1.0
aComplete information available for 6649 women for any nitro-
satable drugs, 6678 women for any secondary amines, 6708 women
for any tertiary amines, and 6701 women for any amides.
bSee Supplemental Table 1 for a listing of nitrosatable drugs.
cMetformin.
dMetoclopramide.
eCarbamazepine.
fHydralazine, clonidine.
gCaffeine.
hSulfamethoxazole.
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third month. In the ﬁrst month of pregnancy, between 40
and 41% (depending on the type of nitrosatable drug
taken) of participants who took nitrosatable drugs did
not take any supplements with vitamin C; the proportion
of nonusers dropped to 12.3% by the third month of
pregnancy.
DISCUSSION
In this population-based study of U.S. women who
gave birth to infants without major birth defects, use of
nitrosatable drugs was fairly common during the ﬁrst
trimester of pregnancy. Nearly one quarter of the
women took such drugs early in pregnancy with an
even higher prevalence of exposure among non-His-
panic white women, women over 40 years of age, and
women with 13 years or more of education. The preva-
lence of nitrosatable drug use was lower during the
periconceptional period than for the ﬁrst trimester,
which might be expected because of the shorter period
(2 vs. 3 months). Regarding maternal race or ethnicity,
age, and education, similar patterns of nitrosatable drug
usage were noted during these periods. Pseudoephe-
drine, a nitrosatable secondary amine that is available
without a prescription, was the most common nitrosat-
able drug in this population. It is also noteworthy that
four of the ﬁve most commonly taken drugs classiﬁed
as nitrosatable tertiary amines are also available over
the counter. During the ﬁrst and second months of
pregnancy, a sizable proportion of women who took
nitrosatable drugs denied taking vitamin supplements
with vitamin C (41.6% and 19.3%, respectively), a well-
documented inhibitor of nitrosation. By the third month
Figure 1. Prevalence (%) of nitrosatable drug use during the ﬁrst trimester by maternal characteristics, National Birth Defects Prevention
control women, 1997–2005. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 2. Prevalence (%) of nitrosatable drug use during the ﬁrst trimester by state of residence, National Birth Defects Prevention Study
control women, 1997–2005. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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plements that most likely contained vitamin C.
Compared with prevalence estimates in previously
published studies, the present study has the highest
reported prevalence of nitrosatable drug use during early
pregnancy. Olshan and Faustman (1989) published one of
the ﬁrst studies on nitrosatable drug use during preg-
nancy. Among 51,228 pregnancies followed between 1959
and 1965 by the U.S. National Collaborative Perinatal
Project, 3.5% of mothers used nitrosatable drugs during
the ﬁrst 4 months of pregnancy, and 11.8% took such
drugs anytime during pregnancy. Users in that study
were more likely to be white, have more education, and
be slightly older than nonusers, which is consistent with
the trends noted in the present study. The investigators
identiﬁed a total of 13 drug components deemed to have
nitrosation potential, far fewer than those identiﬁed in
the more recent NBDPS control population. In a popula-
tion-based, case-control study of childhood brain cancer
that spanned cancer centers in eight states, Carozza et al.
(1995) noted that 5% of control mothers took nitrosatable
drugs anytime during pregnancy; medications taken
included 24 different nitrosatable components.
Three subsequent case-control studies of childhood can-
cer used a broader classiﬁcation scheme for nitrosatable
drugs that was based on published experimental data or
chemical structure (McKean-Cowdin et al., 2003; Cook
et al., 2004; Cardy et al., 2006). Prevalence of any nitrosat-
able drug use among control mothers anytime during
pregnancy ranged from 14.9% to 18.4%, but prevalence of
use during the ﬁrst trimester was not reported in these
studies. Two of these studies also reported prevalences of
nitrosatable intake by chemical group including 7.5 to 9%
for secondary amines, 10 to 13% for tertiary amines, and
2.5 to 3% for amides (McKean-Cowdin et al., 2003; Cardy
et al., 2006). We found the use of nitrosatable drugs in
pregnancy among NBDPS participants substantially to be
more common than in the study populations of these three
studies, most likely because of a more comprehensive clas-
siﬁcation scheme based on a review by Brambilla and Mar-
telli (2007). Another possible reason for the higher preva-
lence of nitrosatable drug use in the present study is that
the index pregnancies of the NBDPS control mothers
occurred more recently (1997–2005) than those of the can-
cer studies (index births occurred before 1995). Some types
of drugs and patterns of use might have changed over
time. In a study of over-the-counter medications taken
during pregnancy, Werler et al. (2005) noted that use of
dextromethorphan, diphenhydramine, and pseudoephe-
drine increased from 1976 to 2004. These drugs were
among the most commonly taken nitrosatable drugs in the
present study. Finally, interviews with the mothers in the
childhood cancer studies predominantly took place more
than 2 years after delivery of the index births and up to 20
years afterward, whereas NBDPS mothers were inter-
viewed within 24 months after the expected due date of
the index pregnancy. Results from several studies suggest
that accuracy of recall may decrease as the span between
pregnancy and maternal interview increases (Wilcox and
Horney, 1984; Koren et al., 2004).
Less research has been conducted on the relation
between maternal nitrosatable drug use and adverse
pregnancy outcomes besides childhood cancer. In several
case-control studies of birth defects, nitrosatable drug use
has ranged from 8.0% (Croen et al., 2001) and 8.7%
(Brender et al., 2004) among control women during the
periconceptional period (deﬁned in both studies as 3
months preconception to 3 months postconception) to
10.7% anytime during pregnancy (Gardner et al., 1998).
Only one previously published study reported nitrosat-
able drug use by class of drug (Cardy et al., 2006). In the
present study, NBDPS study participants took nitrosat-
able drugs that spanned a wide variety of indications
and therapeutic actions. Examining nitrosatable drugs by
indication and pharmacologic action might help to distin-
guish effects caused by nitrosatability from those caused
by other pharmacologic effects or underlying illnesses.
This study provides some of the most recent data on the
prevalence of nitrosatable drug exposure among women
in childbearing years in which populations in all major
regions of the United States are represented. The study
also has several potential limitations. Prevalence estimates
were based on women’s reports of medications taken dur-
ing pregnancy, and the drugs reported were not veriﬁed.
Indeed, validating drug reports is a challenge because
many over-the-counter and prescription drugs are not
recorded in the medical records. In addition, although our
classiﬁcation of nitrosatable drugs is based on the most
extensive published and up-to-date resources available,
not all drugs have been tested. Brambilla and Martelli
(2007) stated in their extensive review of nitrosatable
drugs that ‘‘the number of theoretically nitrosatable drugs
that have not been tested for the possible formation of gen-
otoxic-carcinogenic N-nitroso derivatives is very high.’’
In conclusion, nitrosatable drug use during the ﬁrst tri-
mester was common in this population of U.S. women in
childbearing years. Many of the active ingredients identi-
ﬁed as nitrosatable are available in over-the-counter med-
Table 3
Vitamin C Supplementation
a among Nitrosatable Drug Users during the First Three Months of Pregnancy,
National Birth Defects Prevention Study Control Women, 1997–2005
Nitrosatable
drug taken
Number (%) who took supplement
with vitamin C in the ﬁrst month
postconception
Number (%) who took supplement
with vitamin C in the second
month postconception
Number (%) who took supplement
with vitamin C in the third month
postconception
None
Less than
daily Daily None
Less than
daily Daily None
Less than
daily Daily
Any 652 (41.6) 311 (19.8) 604 (38.5) 303 (19.3) 299 (19.1) 965 (61.6) 193 (12.3) 125 (8.0) 1249 (79.7)
Secondary amine 334 (40.4) 165 (20.0) 327 (39.6) 158 (19.1) 149 (18.0) 519 (62.8) 89 (10.8) 71 (8.6) 666 (80.6)
Tertiary amine 333 (40.8) 175 (21.4) 308 (37.7) 139 (17.0) 176 (21.6) 501 (61.4) 98 (12.0) 67 (8.2) 651 (79.8)
Amide 205 (40.0) 107 (20.9) 200 (39.1) 93 (18.2) 97 (18.9) 322 (62.9) 58 (11.3) 37 (7.2) 417 (81.4)
aSupplementation from single, prenatal, or multi-vitamin preparations.
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Birth Defects Research (Part A) 91:258264 (2011)ications. A substantial proportion of women who took
these medications during the ﬁrst trimester did not take
supplements containing vitamin C on a daily basis until
the third month of pregnancy. More research is needed
regarding the effects of nitrosatable drug use on preg-
nancy outcomes in which the effects of such drugs are
examined by their molecular structure, pharmacologic
actions, and indication of use.
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